Skip to main content
Joel Neal, MD, Oncology, Stanford, CA

Joel W Neal MD PhD


Assistant Professor, Medicine - Oncology, Stanford University Medical Center

Join to View Full Profile
  • 300 Pasteur DrStanford, CA 94305

  • Phone+1 650-723-4000

  • Fax+1 650-498-5840

Dr. Neal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2004 - 2007
  • Northwestern University The Feinberg School of Medicine
    Northwestern University The Feinberg School of MedicineClass of 2004

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2010 - 2025
  • MA State Medical License
    MA State Medical License 2006 - 2011
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Other

Press Mentions

  • Exelixis Announces Results from COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Multiple Advanced Solid Tumor Types
    Exelixis Announces Results from COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Multiple Advanced Solid Tumor TypesMay 13th, 2020
  • Sequencing Switches, Intriguing Combos Being Debated in ALK+ NSCLC
    Sequencing Switches, Intriguing Combos Being Debated in ALK+ NSCLCAugust 8th, 2017
  • Presents State of the Science Summit™: Updates in Management of Adenocarcinoma of the Lung
    Presents State of the Science Summit™: Updates in Management of Adenocarcinoma of the LungJune 12th, 2017
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: